Group 1 - The cosmetics sector increased by 1.05% on August 29, with Jiaheng Jiahua leading the gains [1] - The Shanghai Composite Index closed at 3857.93, up 0.37%, while the Shenzhen Component Index closed at 12696.15, up 0.99% [1] - Jiaheng Jiahua's stock price rose by 20.01% to 31.85, with a trading volume of 138,900 shares and a transaction value of 434 million yuan [1] Group 2 - The cosmetics sector saw a net inflow of 10.35 million yuan from institutional investors, while retail investors contributed a net inflow of 88.15 million yuan [2] - Major stocks in the sector experienced varied capital flows, with Jiaheng Jiahua having a net inflow of 76.21 million yuan from institutional investors [3] - Shanghai Jiahua had a net inflow of 35.86 million yuan from institutional investors, but a net outflow of 51.01 million yuan from retail investors [3]

Market Overview - The cosmetics sector experienced a decline of 4.44% on August 27, with Proya leading the drop [1] - The Shanghai Composite Index closed at 3800.35, down 1.76%, while the Shenzhen Component Index closed at 12295.07, down 1.43% [1] Individual Stock Performance - Key stocks in the cosmetics sector showed varied performance, with Jiahen Jiahua rising by 2.08% to a closing price of 25.03 [1] - Other notable declines included Marubi Biological falling by 2.13% to 40.94, and Shiseido dropping by 3.34% to 25.47 [1][2] Trading Volume and Capital Flow - The total trading volume for the cosmetics sector was significant, with Jiahen Jiahua recording a volume of 195,100 shares and a transaction value of 498 million yuan [1] - The sector saw a net outflow of 580 million yuan from institutional investors, while retail investors contributed a net inflow of 470 million yuan [2] Capital Flow Analysis - Major stocks like Jiahen Jiahua and Marubi Biological experienced mixed capital flows, with Jiahen Jiahua seeing a net outflow of 15.42 million yuan from institutional investors [3] - Conversely, Marubi Biological had a net inflow of 7.79 million yuan from institutional investors, indicating varied investor sentiment across the sector [3]

Core Viewpoint - The company reported a significant decline in both revenue and net profit for the first half of 2025 compared to the previous year [1] Financial Performance - The company's operating revenue for the first half of 2025 was 721 million yuan, representing a year-on-year decrease of 48.67% [1] - The net profit attributable to shareholders of the listed company was 65.297 million yuan, down 84.51% year-on-year [1] - The net profit attributable to shareholders after deducting non-recurring gains and losses was 55.1868 million yuan, a decrease of 86.22% year-on-year [1] - The basic earnings per share were 0.1373 yuan [1]

Core Insights - The company reported a significant decline in revenue and net profit for the first half of 2025, indicating potential challenges in its operational performance [1] Financial Performance - The company achieved an operating income of 721 million yuan, representing a year-on-year decrease of 48.67% [1] - The net profit attributable to shareholders of the listed company was 65.297 million yuan, down 84.51% compared to the previous year [1] - The net profit attributable to shareholders after deducting non-recurring gains and losses was 55.1868 million yuan, reflecting a decline of 86.22% year-on-year [1] - The basic earnings per share were reported at 0.1373 yuan [1]

2025 年上半年非经营性资金占用及其他关联资金往来情况汇总表 公司法定代表人：周旭明 主管会计工作负责人：孟海斌 会计机构负责人：范玉琪 单位：人民币万元 非经营性资金占用 资金占用方名 称 占用方与上 市公司的关 联关系 上市公司 核算的会 计科目 2025 年期 初占用资 金余额 2025 年上半年占 用累计发生金额 （不含利息） 2025 年上半年 占用资金的利息 （如有） 2025 年上半年 偿还累计发生 金额 2025 年上半年 期末占用资金 余额 占用形成 原因 占用性质 控股股东、实际控制人及其附属企业 不适用 不适用 不适用 不适用 不适用 小计 - - - - - 前控股股东、实际控制人及其附属企业 不适用 不适用 不适用 不适用 不适用 小计 - - - - - 其他关联方及附属企业 不适用 不适用 不适用 不适用 不适用 小计 - - - - - 总计 - - - - - 其它关联资金往来 资金往来方名 称 往来方与上 市公司的关 联关系 上市公司 核算的会 计科目 2025 年期 初往来资 金余额 2025 年上半年往 来累计发生金额 （不含利息） 2025 年上半年 往来资金的利息 ...

证券代码：300856 证券简称：科思股份 公告编号：2025-048 债券代码：123192 债券简称：科思转债 南京科思化学股份有限公司 2025 年半年度募集资金存放与使用情况的专项报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 一、募集资金基本情况 （一）首次公开发行股票募集资金 1、实际募集资金金额及到位情况 根据中国证券监督管理委员会证监许可【2020】803 号《关于核 准南京科思化学股份有限公司首次公开发行股票的批复》文件核准， 南京科思化学股份有限公司（以下简称"公司""本公司"）由主承销 商民生证券股份有限公司（以下简称"民生证券"）向社会公众公开 发行人民币普通股（A 股）2,822 万股，每股面值 1.00 元，发行价为 每股 30.56 元，共募集资金 86,240.32 万元，扣除发行费用 7,727.21 万元后，实际募集资金净额为 78,513.11 万元。上述募集资金到位情 况已经天衡会计师事务所（特殊普通合伙）出具的天衡验字（2020） 00071 号《验资报告》验证。 2、以前年度募集资金使用及结余情况 截至 202 ...

南京科思化学股份有限公司 第三届监事会第二十一次会议决议公告 证券代码：300856 证券简称：科思股份 公告编号：2025-045 债券代码：123192 债券简称：科思转债 二、监事会会议审议情况 经与会监事认真审议，形成决议如下： （一）审议通过《关于公司<2025 年半年度报告>及其摘要的议 案》 根据 2025 年半年度经营情况，公司按照相关规定编制了《2025 年半年度报告》及《2025 年半年度报告摘要》。 本 议 案 具 体 内 容 详 见 公 司 同 日 披 露 于 巨 潮 资 讯 网 （www.cninfo.com.cn）的《2025年半年度报告》（公告编号：2025-047） 及《2025 年半年度报告摘要》（公告编号：2025-046）。 表决结果：同意票为 3 票，反对票为 0 票，弃权票为 0 票。 本公司及监事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 一、监事会会议召开情况 南京科思化学股份有限公司（以下简称"公司"）第三届监事会 第二十一次会议于 2025 年 8 月 26 日以现场结合通讯方式召开，会议 通知已于 2025 年 8 ...

（一）审议通过《关于公司<2025 年半年度报告>及其摘要的议 案》 根据 2025 年半年度经营情况，公司按照相关规定编制了《2025 年半年度报告》及《2025 年半年度报告摘要》。 证券代码：300856 证券简称：科思股份 公告编号：2025-044 债券代码：123192 债券简称：科思转债 南京科思化学股份有限公司 第四届董事会第三次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 南京科思化学股份有限公司（以下简称"公司"）第四届董事会 第三次会议于 2025 年 8 月 26 日以现场结合通讯方式召开，会议通知 已于 2025 年 8 月 15 日以通讯方式通知了全体董事。会议应出席董事 9 名，实际出席董事 9 名（其中 2 名董事以通讯方式出席）。会议由 董事长周旭明先生主持，公司其他高级管理人员列席了本次会议。 本次董事会会议的召集、召开和表决程序符合有关法律、行政法 规、部门规章、规范性文件和《公司章程》的规定。 二、董事会会议审议情况 经与会董事认真审议，形成决议如下： 《南京科思化学股份有限公司第 ...

一、保荐工作概述 | 项目 | 工作内容 | | --- | --- | | 1.公司信息披露审阅情况 | | | （1）是否及时审阅公司信息披露文件 | 是 | | （2）未及时审阅公司信息披露文件的次数 | 无 | | 2．督导公司建立健全并有效执行规章制度的情况 | | | （1）是否督导公司建立健全规章制度（包括但不 限于防止关联方占用公司资源的制度、募集资金 | 是 | | 管理制度、内控制度、内部审计制度、关联交易 | | | 制度） | | | （2）公司是否有效执行相关规章制度 | 是 | | 3.募集资金监督情况 | | | （1）查询公司募集资金专户次数 | 6次（2025年1月至2025年6月每月一次） | | （2）公司募集资金项目进展是否与信息披露文件 | 是 | | 一致 | | | 4.公司治理督导情况 | | | （1）列席公司股东大会次数 | 0次 | 1 | （2）列席公司董事会次数 | 0次 | | --- | --- | | （3）列席公司监事会次数 | 0次 | | 5.现场检查情况 | | | （1）现场检查次数 | 1次 | | （2）现场检查报告是否按照深圳证券 ...

Financial Performance - The company reported strong performance in the first half of 2025, with a significant increase in revenue compared to the same period in 2024[13]. - Revenue for the reporting period was ¥721,068,308.56, a decrease of 48.67% compared to ¥1,404,695,117.82 in the same period last year[19]. - Net profit attributable to shareholders was ¥65,296,988.47, down 84.51% from ¥421,489,813.03 year-on-year[19]. - Basic earnings per share decreased to ¥0.1373, down 84.55% from ¥0.8889 in the same period last year[19]. - The company's comprehensive gross margin decreased to 32.05% due to a decline in sunscreen product prices and reduced shipment volumes[34]. - The total operating revenue for the first half of 2025 was ¥721,068,308.56, a decrease of 48.7% compared to ¥1,404,695,117.82 in the first half of 2024[174]. - Net profit for the first half of 2025 was ¥63,081,994.56, a decline of 85.0% from ¥421,223,320.60 in the first half of 2024[175]. - The total comprehensive income for the first half of 2025 was ¥78,994,157.83, a decrease of 81.3% from ¥423,421,211.97 in the first half of 2024[176]. Research and Development - Research and development efforts are being prioritized, particularly in the area of new sunscreen formulations that improve skin protection[12]. - The company holds 204 authorized patents, including 59 invention patents, reflecting its strong research and development capabilities[38]. - Research and development investment decreased by 39.91% to ¥39,021,023.64, attributed to a reduction in employee compensation and material consumption[42]. - The R&D center established by the company is focused on developing new chemical products, with an investment of 6.16 million allocated for ongoing projects[68]. - The company is focusing on the development of high-end sunscreen products, with a projected investment of 2.91 million for research and development[68]. Market Strategy and Expansion - The company is focusing on expanding its market presence through strategic partnerships and potential acquisitions to drive growth[12]. - Future guidance indicates a projected revenue growth of approximately 15% for the second half of 2025, driven by increased demand for innovative products[13]. - The company plans to enhance its digital marketing strategies to better engage with consumers and boost online sales[12]. - The company is actively pursuing market expansion strategies, including potential mergers and acquisitions to enhance its product offerings[68]. - The company plans to launch new product lines in the next quarter, aiming for a market share increase of 9%[68]. Financial Position and Cash Flow - The net cash flow from operating activities was ¥59,675,090.79, reflecting a decline of 89.59% compared to ¥573,293,860.92 in the previous year[19]. - The company's cash and cash equivalents decreased by 317.78% to -¥154,864,642.16, reflecting a significant reduction in cash inflow from operating activities[42]. - The total assets at the end of the reporting period were ¥4,033,708,353.86, a decrease of 5.27% from ¥4,258,154,997.78 at the end of the previous year[19]. - Total current assets decreased from ¥2,064,657,895.12 to ¥1,621,740,378.51, a decline of approximately 21.5%[166]. - Cash and cash equivalents decreased from ¥534,033,998.32 to ¥382,258,855.58, a reduction of about 28.4%[166]. Sustainability and Compliance - The company is committed to sustainability, with new formulations that are environmentally friendly and meet regulatory standards[12]. - The company has established a systematic "raw material +" supply model, enhancing its industry position and competitive advantage through continuous innovation and upgrading of formulation application research[39]. - Environmental compliance remains a priority, with ongoing investments in waste management and pollution control to meet stricter regulations[87]. - The company has committed to low-carbon transformation and has joined the Science Based Targets initiative (SBTi) to support climate commitments[100]. Shareholder and Capital Management - The company plans not to distribute cash dividends, issue bonus shares, or increase capital using reserves[5]. - The company has fully utilized the funds raised from the IPO and has canceled the related special account for the raised funds[63]. - The company has achieved a funding utilization rate of 89.62% for the convertible bonds issued[64]. - The company reported a total of 5,466,818 newly restricted shares due to the 2024 equity distribution plan[138]. - The largest shareholder, Kesi Investment, holds 52.00% of the shares, totaling 247,380,000 shares, with an increase of 70,680,000 shares during the reporting period[140]. Risks and Challenges - The company faces risks from fluctuations in raw material prices, which are critical to maintaining profitability, and has implemented strategies to mitigate these risks[87]. - Export revenue is significantly impacted by exchange rate fluctuations, with a high proportion of sales denominated in USD and EUR, necessitating risk management strategies[88]. - The company is actively monitoring macroeconomic conditions that could impact the personal care industry, which is closely tied to its business performance[87].